Inventurus Knowledge Solutions Ltd

Inventurus Knowledge Solutions Ltd

₹ 1,886 -3.83%
20 Dec - close price
About

Incorporated in 2006, Inventurus Knowledge Solutions Ltd provides healthcare solutions through its care enablement platform[1]

Key Points

Business Overview:[1]
IKSL is a technology-enabled healthcare solutions provider which offer a care enablement platform assisting physician enterprises in the US, Canada and Australia, with a focus on the US markets. It partners with an outpatient and inpatient health care organizations, enabling them to deliver superior clinical care through a **fee for value model **

  • Market Cap 32,355 Cr.
  • Current Price 1,886
  • High / Low 2,148 / 1,851
  • Stock P/E 87.4
  • Book Value
  • Dividend Yield 0.00 %
  • ROCE 30.0 %
  • ROE 37.3 %
  • Face Value 1.00

Pros

  • Company has a good return on equity (ROE) track record: 3 Years ROE 41.6%

Cons

  • Promoter holding has decreased over last quarter: -6.01%
  • Debtor days have increased from 58.4 to 72.7 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 Sep 2024
631 1,283
399 924
Operating Profit 232 359
OPM % 37% 28%
19 12
Interest 2 48
Depreciation 12 57
Profit before tax 237 266
Tax % 13% 22%
205 209
EPS in Rs 12.02 12.16
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
529 553 764 1,031 1,818
367 348 466 639 1,297
Operating Profit 162 205 298 392 521
OPM % 31% 37% 39% 38% 29%
31 16 1 -2 40
Interest 7 8 7 6 61
Depreciation 40 30 23 25 59
Profit before tax 145 183 269 359 442
Tax % 5% 9% 13% 15% 16%
137 165 233 305 370
EPS in Rs 166.73 200.10 13.61 17.86 21.68
Dividend Payout % 0% 12% 393% 0% 46%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 49%
TTM: 76%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 31%
TTM: 12%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: 42%
Last Year: 37%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 8 8 17 17 17 17
Reserves 275 449 630 812 1,141 1,360
0 76 65 52 1,311 935
151 53 75 107 411 479
Total Liabilities 434 586 788 988 2,880 2,791
36 87 76 59 1,833 1,803
CWIP 0 0 0 0 3 1
Investments 1 14 16 32 195 44
397 485 695 898 849 943
Total Assets 434 586 788 988 2,880 2,791

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
163 175 233 288 210
-79 -167 -82 -158 -1,137
-41 -37 -59 -152 780
Net Cash Flow 43 -28 92 -22 -147

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 51 49 46 57 73
Inventory Days
Days Payable
Cash Conversion Cycle 51 49 46 57 73
Working Capital Days 20 48 21 26 6
ROCE % 47% 47% 50% 30%

Shareholding Pattern

Numbers in percentages

2 Recently
Dec 2024
63.72%
4.08%
5.81%
23.52%
2.85%
No. of Shareholders 1,89,761

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents